Ge Li

Enhance Biotech, Inc. engages in the acquisition, development and commercialization of drugs for lifestyle disorders. The company was founded on June 7, 1999 and is headquartered in New York, NY.

BioNumerik Pharmaceuticals, Inc. discovers and develops new medicines for cancer treatment. The firm's products include Tavocept which has the potential to substantially increase patient survival in the most common type of lung cancer and possibly many other forms of cancer, and Karenitecin which is an investigational new anti-tumor drug in the camptothecin class of chemotherapy drugs. The company was founded by Frederick H. Hausheer on December 15, 1992 and is headquartered in San Antonio, TX.

ChemDiv, Inc. operates as a discovery and development contract research organization. It specializes in early and clinical development of anti-infectives and antivirals, oncologics, CNS, cardiometabolics, and anti-inflammatory therapies. The firm?s services include synthetic chemistry, structural biology and structure-based drug discovery, molecular modeling, medicinal chemistry, scale-up, biochemical and cellular assay development, analytical/bioanalytical platforms, ADME/tox, DMPK, and multiple in vivo efficacy/tox models. The company was founded by Alexander Ivachtchenko in 1991 and is headquartered in San Diego, CA.

SCILEX Pharmaceuticals, Inc. engages in the development and commercialization of pharmaceutical products. It acquires late-stage clinical development and sales and marketing of generic and branded generic products. Its product includes ZTlido. The company was founded by Anthony P. Mack and William Pedranti in 2011 and is headquartered in Berwyn, PA.

American Chemical Society engages as a scientific society which supports scientific inquiry in the field of chemistry. The company was founded in 1876 and is headquartered in Washington, DC.

Ardent Pharmaceuticals, Inc. researches and develops drugs for pain, urinary incontinence, premature ejaculation, depression and cardio protection. The company is headquartered in New York, NY.

Global Factory, Inc. provides collaborative manufacturing execution systems. The firm's software gather, organize & analyze demand, production & quality data from various sources and monitor key indicators & execute business processes to control, manage & optimize distributed manufacturing operations. The company was founded in 1999 and is headquartered in Santa Clara, CA.

The American Association of Pharmaceutical Scientists engages in research and development of pharmaceutical products. The private company is based in Arlington, VA. The company was founded by Leslie Z. Benet.

Shanghai Stock Exchange provides marketplace and facilities for securities trading. Its services include formulating business rules, accepting and arranging listings, organizing and monitoring securities trading, regulating members & listed companies, managing, and disseminating market information. The company was founded on November 26, 1990 and is headquartered in Shangha, China

Part of New Wuxi Life Science Holdings Ltd., XenoBiotic Laboratories, Inc. is a company that provides bioanalytical, drug metabolism, and pharmacokinetic services. The company is based in Plainsboro, NJ. The company was founded by Jinn Wu. Jinn Wu has been the CEO since incorporation. XenoBiotic Laboratories was acquired by Wuxi PharmaTech (Cayman), Inc. on October 01, 2014.

Shanghai Syn-the-all Pharmaceutical Co. Ltd. engages in the manufacture, research and development of generic drugs. The company offers active pharmaceutical ingredients and finished forms. It provides API process development, small molecule Active pharmaceutical ingredients, analytical development and quality control, antibody drug conjugate services. It serves life science industry. Shanghai Syn-the-all Pharmaceutical was founded on January 23, 2003 and is headquartered in Shanghai, China.

6 Dimensions Capital is an independent private equity firm headquartered in China. The firm was founded in 2017.

MaveriX Oncology, Inc. operates as a a biotechnology company. It focuses on the discovery, development, and commercialization of targeted small molecule cancer chemo-immunotherapies. The company was founded by Steven A. Everett and Craig Alan Coburn in 2015 and is headquartered in Palo Alto, CA.

BridgeBio Pharma LLC engages in the discovery and development of pharmaceutical drugs for patients with genetic diseases. It offers transthyretin stabilizer, SHP2 inhibitor, KRAS inhibitor, Collagen 7 replacement, and S1P-lyase inhibitor. The company was founded by Neil Kumar and is headquartered in Palo Alto, CA.

Part of BridgeBio Pharma, Inc., QED Therapeutics, Inc. is a biotechnology company based in Palo Alto, CA. The company focuses on precision medicine for FGFR-driven diseases and is committed to finding solutions to FGFR-driven cancers and diseases to give patients more possibilities. QED Therapeutics' lead investigational candidate is infigratinib, an orally administered, FGFR1-3 selective tyrosine kinase inhibitor that has shown activity in patients with chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions and advanced urothelial carcinoma with FGFR3 genomic alterations. In 2020, QED submitted a new drug application (NDA) with the Food and Drug Administration for second- and later-line cholangiocarcinoma. Michael Henderson has been the CEO of the company since 2017.

Part of BridgeBio Pharma, Inc., Origin Biosciences, Inc. is an actively managed investment issuer focused on making equity investments in psychedelics industry-related companies to provide investors with diverse exposure to the sector. The company is based in Palo Alto, CA. The company, led by a team of industry experts, leverages its management expertise, professional network, and due diligence process to identify and invest in leading and emerging companies focused on the emerging psychedelics sector. Michael Henderson has been the CEO of the company since 2018.

AiViva BioPharma, Inc. is a clinical stage biotech company based in Costa Mesa, CA. AiViva is developing new therapeutics using innovative approaches, with proprietary technologies, including Jel™, to address high unmet medical needs through focal therapies that target diseases of neovascularization, abnormal cell proliferation, and fibrosis. The private company's core competencies include the development of novel drugs in specialty therapeutic areas of dermatology, ophthalmology, urology, and oncology. An estimated 100 million people in the developed world form scars following surgery. The company was founded in 2015 by Diane Tang-Liu, who has been the CEO since then.

Part of Sorrento Therapeutics, Inc., Nanjing Levena Biopharma Co. Ltd. manufactures and supplies biopharmaceutical products.

Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA.